LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1060 participants.

Also called NCT02077257

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,060 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as a collaborator
Registry
  • NCT NCT02077257
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02077257. Randomized; no masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients
Condition
Acute Coronary Syndrome
Intervention (Drug)
Rosuvastatin
Lead sponsor
Committee of Cardio-Cerebral-Vascular Diseases of GSC (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02077257
Content hash
b3b547232b5051bd21c432bd0fc146b602fa612c0ec0f76190b4a6fc44337b53